Experimental drug aims to halt rare neurological decline
NCT ID NCT07681713
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This Phase 3 trial tests whether vatiquinone can slow the progression of Friedreich's ataxia, a rare genetic disorder that damages the nervous system and impairs movement. About 120 adults with moderate symptoms will take the drug for 24 months. Researchers will measure changes in movement, balance, and daily activities to see if the treatment preserves function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vatiquinone
What this could lead to
If successful, vatiquinone could become the first treatment to slow the progression of Friedreich's ataxia, preserving mobility and daily function for longer.
What could go wrong
This is a Phase 3 trial, but results may not show a clear benefit. The drug may cause side effects, and what works in this study may not help all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRIEDREICH'S ATAXIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- MRS Biomarker Study in Friedreich's Ataxia (NCT07635030)
- Friedreich's Ataxia Genetic Study INTREP-AF (NCT04346238)
- NAD+ and Exercise for Friedreich's Ataxia - NCT04192136
- Cardiac output and fatigue in Friedreich's ataxi NCT07444333
- Biomarkers in Friedreich's Ataxia Study | NCT02497534
- EFACTS Friedreich's Ataxia Registry Study (NCT02069509)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••